Home
Seikagaku

Seikagaku Market Share Analysis for July 2026

生化学工業株式会社のホームをご覧いただけます。

Health > Biotechnology and Pharmaceuticals

Domainseikagaku.co.jp

Year Founded1947

Employees501 - 1000

Annual Revenue$200M - $500M

Seikagaku

Seikagaku (including company regionals)

seikagaku.co.jp

See more website traffic and engagement information

Seikagaku Revenue up to July 2026 is 200M - 500M

revenue generated by Seikagaku top domains

Seikagaku top domains revenue over 3 years

Revenue for Seikagaku top domains

seikagaku.co.jp200M - 500M

See more with Sales Intelligence

Total visits to Seikagaku's top domains

Understand Seikagaku market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

seikagaku.co.jp9.8K

See more with Sales Intelligence

Avg. visit duration in Seikagaku's top domains

Analyze Seikagaku engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

seikagaku.co.jp00:01:22

See more with Sales Intelligence

Avg. pageviews on Seikagaku's top domains

See how Seikagaku keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

seikagaku.co.jp2.45

See more with Sales Intelligence

Seikagaku top competitors by domain

Top similar sites in July 2026, ranked by their affinity

bicycletherapeutics.comCompany NameBicycle TherapeuticsEmployees201 - 500HQUnited Kingdom, CambridgeAnnual revenue$25M - $50MTotal visits8.2KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Seikagaku

These are the website technologies, by industry, used by Seikagaku top domains

Advertising (6)

Google Adsense

Conversion & Analytics (2)

Google Analytics

Mobile (2)

Meta Viewport

Content Management System (1)

ShareWith

More Technologies

5

See all

News & Signals from Seikagaku

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsSeikagaku Corporation launched HyLink on Jan 1st '21.In 2021, Seikagaku Corporation introduced HyLink, a vicosupplement for treating osteoarthritis, and Conturas Bulkamid injection portfolio was acquired by Axonics Modulation Technologies Inc.

NewsSeikagaku Corporation launched HyLink on Aug 1st '21.For instance, Seikagaku Corporation introduced HyLink, an intra-articular single-injection Visco supplement for the treatment of knee osteoarthritis, in Taiwan through TCM Biotech International Corp. in August 2021.

NewsSeikagaku Corporation launched Hylink on Aug 1st '21.In August 2021, Seikagaku announced the launch of Hylink®, an intra-articular single injection Viscosupplement for Knee Osteoarthritis treatment in Taiwan.